Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $700.00

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received an average recommendation of “Hold” from the three brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $700.00.

A number of analysts recently commented on ATRA shares. StockNews.com upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ:ATRA opened at $8.23 on Friday. The business has a fifty day moving average of $14.97 and a 200-day moving average of $16.44. The firm has a market cap of $39.67 million, a PE ratio of -0.15 and a beta of 0.54. Atara Biotherapeutics has a twelve month low of $4.96 and a twelve month high of $63.38.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($5.75) EPS for the quarter, topping analysts’ consensus estimates of ($9.25) by $3.50. The firm had revenue of $27.36 million during the quarter, compared to analyst estimates of $27.00 million. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 671.70%. On average, analysts anticipate that Atara Biotherapeutics will post -15.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other Atara Biotherapeutics news, EVP Anhco Nguyen sold 1,715 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $26,582.50. Following the transaction, the executive vice president now owns 35,939 shares in the company, valued at $557,054.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Anhco Nguyen sold 1,715 shares of Atara Biotherapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $26,582.50. Following the transaction, the executive vice president now owns 35,939 shares in the company, valued at approximately $557,054.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Pascal Touchon sold 3,260 shares of Atara Biotherapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.50, for a total value of $50,530.00. Following the transaction, the chief executive officer now owns 73,165 shares in the company, valued at approximately $1,134,057.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,120 shares of company stock worth $94,860. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors have recently bought and sold shares of the company. Delap Wealth Advisory LLC bought a new stake in Atara Biotherapeutics in the 1st quarter valued at approximately $29,000. Vontobel Holding Ltd. acquired a new position in shares of Atara Biotherapeutics during the 4th quarter worth approximately $41,000. Josh Arnold Investment Consultant LLC increased its position in shares of Atara Biotherapeutics by 17.6% during the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30,000 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Atara Biotherapeutics by 368.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 164,206 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.